Cargando…

Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes

BACKGROUND: Hospital inpatient care for patients with diabetes was estimated to cost $76 billion in 2012. Substantial expense resulted from those patients having multiple hospitalizations. The objective was to compare the risk for diabetes–related hospital readmission in patients with type 2 diabete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heaton, Pamela C., Desai, Vibha C. A., Kelton, Christina M. L., Rajpathak, Swapnil N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719386/ https://www.ncbi.nlm.nih.gov/pubmed/26786291 http://dx.doi.org/10.1186/s12902-016-0084-z

Ejemplares similares

Sulfonylurea: Personalized Medicine for Type 2 Diabetes
por: Hwang, You-Cheol
Publicado: (2015)

Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK
por: Lautsch, Dominik, et al.
Publicado: (2019)

Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force
por: Kalra, Sanjay, et al.
Publicado: (2018)

Statin Therapy and Risk of Developing Type 2 Diabetes: A Meta-Analysis
por: Rajpathak, Swapnil N., et al.
Publicado: (2009)

Impact of Environmental Factors on Differences in Quality of Medication Use: An Insight for the Medicare Star Rating System
por: Desai, Vibha, et al.
Publicado: (2016)

Pioglitazone and sulfonylureas: effectively treating type 2 diabetes
por: Hanefeld, M
Publicado: (2007)

Sulfonylureas and their use in clinical practice
por: Sola, Daniele, et al.
Publicado: (2015)

Commentary on “Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus: International Task Force”
por: Singh, S. K.
Publicado: (2018)

A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas
por: Li, Josephine H., et al.
Publicado: (2021)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
por: Min, Se Hee, et al.
Publicado: (2015)

Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study
por: Tang, Yuexin, et al.
Publicado: (2020)

Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease
por: Emdin, Connor A., et al.
Publicado: (2017)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Severity of hypoglycaemia and health‐related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe
por: Pawaskar, Manjiri, et al.
Publicado: (2018)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Antidiabetic Effects of Add-On Gynostemma pentaphyllum Extract Therapy with Sulfonylureas in Type 2 Diabetic Patients
por: Huyen, V. T. T., et al.
Publicado: (2012)

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
por: Fulcher, Greg, et al.
Publicado: (2015)

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program
por: Crandall, Jill P, et al.
Publicado: (2017)

Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
por: Baker, Matthew C., et al.
Publicado: (2023)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
por: Yang, Yeoree, et al.
Publicado: (2016)

Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus
por: Tang, Yuexin, et al.
Publicado: (2018)

Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis
por: Ahn, Sang Bong, et al.
Publicado: (2020)

Use of the Estimated Glucose Disposal Rate as a Measure of Insulin Resistance in an Urban Multiethnic Population With Type 1 Diabetes
por: Epstein, Eric J., et al.
Publicado: (2013)

Sulfonylurea and Cancer Risk Among Patients With Type 2 Diabetes: A Population-Based Cohort Study
por: Zhao, Houyu, et al.
Publicado: (2022)

Initial Sulfonylurea Use and Subsequent Insulin Therapy in Older Subjects with Type 2 Diabetes Mellitus
por: Fu, Alex Z., et al.
Publicado: (2012)

Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea: study in a Japanese Hospital Database
por: Tanabe, Makito, et al.
Publicado: (2015)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Concurrent Use of Oral Anticoagulants and Sulfonylureas in Individuals With Type 2 Diabetes and Risk of Hypoglycemia: A UK Population-Based Cohort Study
por: Alwafi, Hassan, et al.
Publicado: (2022)

Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

Correction to: Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
por: Al-Saleh, Yousef, et al.
Publicado: (2021)

Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis
por: Yen, Fu-Shun, et al.
Publicado: (2020)

Effect of Medication Copayment on Adherence and Discontinuation in Medicare Beneficiaries with Type 2 Diabetes: A Retrospective Administrative Claims Database Analysis
por: Pawaskar, Manjiri D., et al.
Publicado: (2018)

Sulfonylureas: Asset or liability?
por: Lakhani, Om J., et al.
Publicado: (2015)

Sulfonylureas at the Glomerular Battlefield
por: Kalra, Sanjay, et al.
Publicado: (2018)

Sulfonylurea Use in Patients with Type 2 Diabetes and COPD: A Nationwide Population-Based Cohort Study
por: Yen, Fu-Shun, et al.
Publicado: (2022)

TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes
por: Holstein, Andreas, et al.
Publicado: (2011)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Sulfonylureas in the Treatment of Type 2 Diabetes Mellitus: A Fresh Look and New Insights
por: Alzaid, Aus
Publicado: (2020)

Genetic Variants Associated with Poor Responsiveness to Sulfonylureas in Filipinos with Type 2 Diabetes Mellitus
por: Paz-Pacheco, Elizabeth, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s8ohn8shp7d9ss920upr9vh096